ELVIO G SILVA, MD
Medical Practice at Holcombe Blvd, Houston, TX

License number
Texas C52355
Category
Medical Practice
Type
Specialist
License number
Texas F5375
Category
Medical Practice
Type
Anatomic Pathology
License number
Texas C52355
Category
Medical Practice
Type
Anatomic Pathology
License number
Texas 009580
Category
Medical Practice
Type
Anatomic Pathology
Address
Address
1515 Holcombe Blvd, Houston, TX 77030
Phone
(713) 792-6161
(713) 792-2991

Personal information

See more information about ELVIO G SILVA at radaris.com
Name
Address
Phone
Elvio Silva, age 81
6314 Auden St, Houston, TX 77005
(713) 249-9059
Elvio Silva
Houston, TX
(713) 432-7699
Elvio Guillermo Silva, age 81
12131 Springer St, Houston, TX 77087
(281) 933-4795
Elvio Guillermo Silva, age 81
13415 Myrtlea Dr, Houston, TX 77079
(713) 467-6924
Elvio Guillermo Silva, age 81
1515 Holcombe Blvd, Houston, TX 77030
(713) 792-7090

Professional information

Elvio Guillermo Silva Photo 1

Elvio Guillermo Silva, Houston TX

Specialties:
Pathology, Anatomic Pathology, Pathology Recertification, Clinical Pathology/Laboratory Medicine
Work:
MD Anderson Cancer Ctr
1515 Holcombe Blvd, Houston, TX 77030
Education:
Universidad Nacional De La Plata (1969)


Elvio Silva Photo 2

Methods Of Identifying Patients With Ovarian Epithelial Neoplasms Based On High-Resolution Mass Spectrometry

US Patent:
2013009, Apr 11, 2013
Filed:
Jun 9, 2011
Appl. No.:
13/703444
Inventors:
Elvio G. Silva - Houston TX, US
Cristina Fente Sampayo - Lugo, ES
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX
International Classification:
G01N 33/68, A61B 10/02, A61B 5/055, A61B 8/12, A61B 6/03
US Classification:
600411, 436 86, 436 87, 530324, 600437, 600427, 600562
Abstract:
Methods for identifying patients with ovarian neoplasms are provided herein comprising performing an assay step of detecting a metabolite in a serum sample of a patient where the metabolite is probably not produced by a tumor but could induce the development of a tumor, and the presence of the metabolite being indicative of an increased likelihood that the patient has ovarian cancer,